Eli Lilly and Company Cash Flow Conversion Efficiency
Eli Lilly and Company cash flow conversion efficiency. Based on the latest financial reports, Eli Lilly and Company (LLY) has a cash flow conversion efficiency ratio of 0.316x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.69 Billion) by net assets ($33.88 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eli Lilly and Company (1989–2025)
Cash flow conversion efficiency of Eli Lilly and Company from 1989 to 2025. This chart illustrates how Eli Lilly and Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eli Lilly and Company (LLY) share price today for real-time trading data and today's change.
Eli Lilly and Company Cash Flow Conversion Ratio Explained
Eli Lilly and Company cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eli Lilly and Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eli Lilly and Company ranked by their cash flow conversion efficiency. Also see LLY company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meta Platforms Inc.
NASDAQ:META
|
0.122x |
|
Meta Platforms Inc.
SA:M1TA34
|
0.122x |
|
Tesla Inc
NASDAQ:TSLA
|
0.054x |
|
Alphabet Inc Class C
NASDAQ:GOOG
|
0.061x |
|
Space Exploration Technologies Corp. Class A Common Stock
NASDAQ:SPCX
|
0.019x |
|
SK Hynix Inc. American Depositary Shares
NASDAQ:SKHY
|
0.249x |
|
Walmart Inc
SA:WALM34
|
0.286x |
|
Samsung Electronics Co Ltd
KO:005930
|
0.055x |
Annual Cash Flow Conversion Efficiency for Eli Lilly and Company (1989–2025)
The table below shows the annual cash flow conversion efficiency of Eli Lilly and Company from 1989 to 2025. Review Eli Lilly and Company free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.54 Billion | $16.81 Billion | 0.634x | +2.55% |
| 2024-12-31 | $14.27 Billion | $8.82 Billion | 0.618x | +58.30% |
| 2023-12-31 | $10.86 Billion | $4.24 Billion | 0.390x | -40.64% |
| 2022-12-31 | $10.78 Billion | $7.08 Billion | 0.657x | -17.10% |
| 2021-12-31 | $9.15 Billion | $7.26 Billion | 0.793x | -28.92% |
| 2020-12-31 | $5.83 Billion | $6.50 Billion | 1.116x | -37.73% |
| 2019-12-31 | $2.70 Billion | $4.84 Billion | 1.792x | +253.85% |
| 2018-12-31 | $10.91 Billion | $5.52 Billion | 0.506x | +5.22% |
| 2017-12-31 | $11.67 Billion | $5.62 Billion | 0.481x | +39.70% |
| 2016-12-31 | $14.08 Billion | $4.85 Billion | 0.345x | +69.56% |
| 2015-12-31 | $14.59 Billion | $2.96 Billion | 0.203x | -29.87% |
| 2014-12-31 | $15.39 Billion | $4.46 Billion | 0.290x | -10.88% |
| 2013-12-31 | $17.64 Billion | $5.74 Billion | 0.325x | -9.46% |
| 2012-12-31 | $14.77 Billion | $5.30 Billion | 0.359x | -32.82% |
| 2011-12-31 | $13.54 Billion | $7.23 Billion | 0.534x | -3.24% |
| 2010-12-31 | $12.41 Billion | $6.86 Billion | 0.552x | +21.36% |
| 2009-12-31 | $9.53 Billion | $4.34 Billion | 0.455x | -57.98% |
| 2008-12-31 | $6.74 Billion | $7.30 Billion | 1.083x | +181.95% |
| 2007-12-31 | $13.42 Billion | $5.15 Billion | 0.384x | +6.10% |
| 2006-12-31 | $10.98 Billion | $3.98 Billion | 0.362x | +104.20% |
| 2005-12-31 | $10.79 Billion | $1.91 Billion | 0.177x | -32.52% |
| 2004-12-31 | $10.92 Billion | $2.87 Billion | 0.263x | -29.64% |
| 2003-12-31 | $9.76 Billion | $3.65 Billion | 0.373x | +49.22% |
| 2002-12-31 | $8.27 Billion | $2.07 Billion | 0.250x | -51.44% |
| 2001-12-31 | $7.10 Billion | $3.66 Billion | 0.515x | -16.47% |
| 2000-12-31 | $6.05 Billion | $3.73 Billion | 0.617x | +18.09% |
| 1999-12-31 | $5.01 Billion | $2.62 Billion | 0.523x | -11.98% |
| 1998-12-31 | $4.43 Billion | $2.63 Billion | 0.594x | +18.86% |
| 1997-12-31 | $4.81 Billion | $2.40 Billion | 0.500x | +53.01% |
| 1996-12-31 | $6.10 Billion | $1.99 Billion | 0.326x | -2.80% |
| 1995-12-31 | $5.43 Billion | $1.82 Billion | 0.336x | +17.39% |
| 1994-12-31 | $5.36 Billion | $1.53 Billion | 0.286x | -13.83% |
| 1993-12-31 | $4.57 Billion | $1.52 Billion | 0.332x | +9.49% |
| 1992-12-31 | $4.89 Billion | $1.48 Billion | 0.303x | +20.03% |
| 1991-12-31 | $4.97 Billion | $1.25 Billion | 0.253x | -40.59% |
| 1990-12-31 | $3.47 Billion | $1.47 Billion | 0.425x | +54.71% |
| 1989-12-31 | $3.76 Billion | $1.03 Billion | 0.275x | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more